Assessing antiangiogenic therapy response by DCE-MRI: Development of a physiology driven multi-compartment model using population pharmacometrics

PLoS ONE

Volumn 6, Issue 10, 2011, Pages

  Steingoetter, Andreas ^a,b   Menne, Dieter ^c   Braren, Rickmer F ^d  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b ETH ZURICH   (Switzerland)

^c Menne Biomed Consulting   (Germany)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GADOLINIUM PENTETATE; GADOLINIUM PENTETATE MEGLUMINE; ANGIOGENESIS INHIBITOR; CONTRAST MEDIUM; DIAGNOSTIC AGENT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIANGIOGENIC THERAPY; ARTICLE; BAYES THEOREM; CANCER TISSUE; COMPARTMENT MODEL; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DRUG TISSUE LEVEL; DYNAMIC CONTRAST ENHANCED MAGNETIC RESONANCE IMAGING; HISTOLOGY; LIVER; LIVER CELL CARCINOMA; MONTE CARLO METHOD; MTL3 MODEL; MUSCLE TISSUE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PHARMACOKINETIC MODEL; PHYSIOLOGICAL PROCESS; PROBABILITY; PROCESS DEVELOPMENT; RAT; TREATMENT RESPONSE; ANALYSIS OF VARIANCE; ANIMAL; BIOLOGICAL MODEL; CARDIOVASCULAR SYSTEM; DRUG EFFECT; LIVER TUMOR; MALE; METABOLISM; NECROSIS; NONLINEAR SYSTEM; PATHOPHYSIOLOGY; TREATMENT OUTCOME;

RATTUS;

ANALYSIS OF VARIANCE; ANGIOGENESIS INHIBITORS; ANIMALS; CARCINOMA, HEPATOCELLULAR; CARDIOVASCULAR SYSTEM; CONTRAST MEDIA; GADOLINIUM DTPA; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MODELS, BIOLOGICAL; NECROSIS; NONLINEAR DYNAMICS; RATS; TREATMENT OUTCOME;

EID: 80054716825     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0026366     Document Type: Article

References (20)

1. Brix G, Griebel J, Kiessling F, Wenz F, (2010) Tracer kinetic modelling of tumour angiogenesis based on dynamic contrast-enhanced CT and MRI measurements. Eur J Nucl Med Mol Imaging 37 (Suppl 1): S30-51.
2. Tofts PS, Brix G, Buckley DL, Evelhoch JL, Henderson E, et al. (1999) Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging 10: 223-232.
3. Yankeelov TE, Luci JJ, Lepage M, Li R, Debusk L, et al. (2005) Quantitative pharmacokinetic analysis of DCE-MRI data without an arterial input function: a reference region model. Magn Reson Imaging 23: 519-529.
4. Steingoetter A, Svensson J, Kosanke Y, Botnar RM, Schwaiger M, et al. (2011) Reference region-based pharmacokinetic modeling in quantitative dynamic contract-enhanced MRI allows robust treatment monitoring in a rat liver tumor model despite cardiovascular changes. Magn Reson Med 65: 229-238.
5. Spiegelhalter DJ, Best NG, Carlin BP, van der Linde A, (2002) Bayesian measures of model complexity and fit. J R Statist Soc B 64: 583-639.
6. DiMeola HJ, Siegel NJ, Kaufman JM, Hayslett JP, (1974) Evaluation of the constant-infusion technique to determine inulin clearance in the rat. J Appl Physiol 36: 261-263.
7. Hastie TJ, Tibshirani RJ, (1990) Generalized Additive Models New York Chapman and Hall/CRC.
8. R Development Core Team (2008) R: A Language and Environment for Statistical Computing. Vienna, Austria. ISBN 3-900051-07-0, URL http://www.R-project.org.: R Foundation for Statistical Computing.
9. Jonsson EN, Karlsson MO, (1999) Xpose-an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed 58: 51-64.
10. Beal S, Sheiner LB, Boeckmann A, Bauer RJ, (2009) NONMEM User's Guides. (1989-2009). Icon Development Solutions, Ellicott City, MD, USA.
11. Plummer M, Best N, Cowles K, Vines K, (2006) CODA: Convergence diagnosis and output analysis for MCMC. R News 6: 7-11.
12. Lunn DJ, Best N, Thomas A, Wakefield J, Spiegelhalter D, (2002) Bayesian analysis of population PK/PD models: general concepts and software. J Pharmacokinet Pharmacodyn 29: 271-307.
13. Schmid VJ, Whitcher B, Padhani AR, Taylor NJ, Yang GZ, (2009) A Bayesian hierarchical model for the analysis of a longitudinal dynamic contrast-enhanced MRI oncology study. Magn Reson Med 61: 163-174.
14. Schmid VJ, Whitcher B, Padhani AR, Taylor NJ, Yang GZ, (2006) Bayesian methods for pharmacokinetic models in dynamic contrast-enhanced magnetic resonance imaging. IEEE Trans Med Imaging 25: 1627-1636.
15. Whitcher B, Schmid VJ, Collins DJ, Orton MR, Koh DM, et al. (2011) A Bayesian hierarchical model for DCE-MRI to evaluate treatment response in a phase II study in advanced squamous cell carcinoma of the head and neck. MAGMA 24: 85-96.
16. Brendel K, Dartois C, Comets E, Lemenuel-Diot A, Laveille C, et al. (2007) Are population pharmacokinetic and/or pharmacodynamic models adequately evaluated? A survey of the literature from 2002 to 2004. Clin Pharmacokinet 46: 221-234.
17. Kärcher JC, Schmid VJ, (2010) Two Tissue Compartment Model in DCE-MRI: A Bayesian Approach. ISBI'10 Proceedings of the 2010 IEEE international conference on Biomedical imaging From Nano to Macro pp. 724-727.
18. Sheiner L, (1985) TUTORIAL SECTION Analysis of Pharmacokinetic Data Using Parametric Models. II. Point Estimates of an Individual's Parameters. Journal of Pharmacokinetics and Biopharmaceutics 13: 515-540.
19. Kwon Y, (2001) Handbook of essential pharmacokinetics, pharmacodynamics, and drug metabolism for industrial scientists New York Kluwer Academic/Plenum Publishers.
20. Gabrielsson J, Weiner D, (2007) Pharmacokinetic/pharmacodynamic data analysis: concepts and applications Stockholm Apotekarsocieteten.